Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Fidelity National Information Servcs Inc (FIS) Price & Performance

BridgeBio Pharma IncTrade
Fidelity National Information Servcs IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Fidelity National Information Servcs Inc — how do they compare? BridgeBio Pharma Inc trades at $84.17 (market cap $16.36B), while Fidelity National Information Servcs Inc trades at $41.61 (market cap $22.05B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOFIS
Market Cap
$16.36B$22.05B
Sector
HealthTechnology
52-Week High
$90.17$72.77
52-Week Low
$47.29$37.72
Enterprise Value
$18.14B$42.56B
Dividend Yield
4.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

Fidelity National Information Servcs Inc

FIS trades at $41.64, down 2.05% today, with technical indicators showing bearish momentum despite attractive valuation metrics including a P/E of 6.57 and P/S of 1.82. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, while lowering full-year guidance due to capital markets weakness. Recent developments include global expansion of Digital One Commercial platform and recognition as world's best treasury management software.

FIS presents a compelling value opportunity with strong banking solutions growth and improving cash flow, though near-term headwinds in capital markets create uncertainty. The stock trades at a discount to analyst consensus target of $50.18, with 58% of analysts maintaining buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS